Search
Search peptide topics
Search across peptide names, aliases, use cases, regulatory updates, and evidence guides.
Peptide profile
12Semaglutide
The active ingredient behind Ozempic, Wegovy, and Rybelsus, useful for separating product-specific label evidence from compounded or research-use claims.
1 evidence areas / Approved for specific usePeptide profileTirzepatide
The active ingredient in Mounjaro and Zepbound, with strong product-specific evidence for type 2 diabetes, chronic weight management, and OSA in adults with obesity.
1 evidence areas / Approved for specific usePeptide profileRetatrutide
An investigational once-weekly triple agonist peptide with strong human weight-loss and glycemic-control signals, unresolved approval status, and high gray-market product-quality risk.
5 evidence areas / Investigational / not approvedPeptide profileCagrilintide
An investigational long-acting amylin analogue with controlled human weight-management evidence and clear FDA limits around compounding and online product claims.
5 evidence areas / Investigational / not approvedPeptide profileCagriSema
Novo Nordisk's investigational cagrilintide-plus-semaglutide program, with phase 3 human weight-management evidence and separate risks for compounded or online combinations.
5 evidence areas / Investigational / not approvedPeptide profileCartalax
A cartilage-oriented tripeptide where preclinical chondrocyte support, weak legacy symptom reports, and product-identity drift need to be kept separate.
2 evidence areas / Varies by product and jurisdictionPeptide profileBPC-157
A heavily promoted repair and gut peptide where human evidence is still limited to a few narrow sources and FDA-flagged compounding concerns.
2 evidence areas / Not FDA-approved for listed usesPeptide profileKPV
A short alpha-MSH-derived peptide motif with preclinical gut-inflammation, delivery, and antimicrobial literature, but no direct human KPV efficacy evidence found.
2 evidence areas / Investigational / not approvedPeptide profileGHK-Cu
A copper-binding tripeptide with route-specific topical skin and wound evidence, plus much weaker systemic, hair, blend, and injectable claim areas.
2 evidence areas / Varies by product and jurisdictionPeptide profileTB-500
A recovery-focused peptide name where the first question is whether the source means the TB-500 fragment, full-length thymosin beta-4, or a market vial.
2 evidence areas / Investigational / not approvedPeptide profileThymosin beta-4
A full-length thymosin beta-4 topic with human ophthalmic, wound, and registry context that must stay separate from TB-500 fragment claims.
4 evidence areas / Investigational / not approvedPeptide profileLL-37
LL-37 has host-defense biology, narrow human chronic-wound evidence, and prominent FDA compounding-risk concerns.
4 evidence areas / Investigational / not approved